Biohit Oyj

Laippatie 1 , 00880 Helsinki
Finland

Telephone +358 9 773861
Fax +358 9 7732867
info@biohit.fi

Trade fair hall

  • Hall 2 / C27
 Interactive Plan

Hall map

MEDICA 2016 hall map (Hall 2): stand C27

Fairground map

MEDICA 2016 fairground map: Hall 2

Our range of products

Product categories

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.02  Anemia related / Vitamin tests

Anemia related / Vitamin tests

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.02  Anemia related / Vitamin tests
  • 03.02.02.01  Diagnostic agents / kits for vitamin determination

Diagnostic agents / kits for vitamin determination

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.03  Auto-immune diseases

Auto-immune diseases

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.03  Auto-immune diseases
  • 03.02.03.02  Diagnostics / kits for the gastro enterology

Diagnostics / kits for the gastro enterology

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.15  Rapid tests - Immunochemistry

Rapid tests - Immunochemistry

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.15  Rapid tests - Immunochemistry
  • 03.02.15.02  Infectious disease tests

Infectious disease tests

Company news

Date

Topic

Download

Nov 14, 2016

Biohit Oyj unveils groundbreaking GastroPanel® quick test

Biohit Oyj Press Release November 14, 2016 at 9:30 am local time (EET)

GastroPanel® quick test can be performed during a clinical appointment from a fingertip blood drop. The new test is an advanced version of Biohit´s unique GastroPanel® stomach health test. GastroPanel® quick test differs from the current clinical test version by giving the results immediately during a single clinical appointment. The GastroPanel® quick test saves costs and unnecessary clinical appointments as well as speeds up the referral to further examinations and eventual treatment, which significantly improves the patient safety.

More Less

Nov 8, 2016

Acetium capsule prevents the exposure to carcinogenic acetaldehyde in patients with atrophy of the stomach mucosa

Biohit Oyj Press Release November 8, 2016 at 09:30 am local time (EET)

New scientific evidence on Acetium capsule has been obtained. A collaborative study with Uppsala University shows that Acetium capsule prevents acetaldehyde exposure in patients suffering from the atrophy of the stomach mucosa (atrophic gastritis) caused by Helicobacter pylori infection. The scientific report has recently been published in Scandinavian Journal of Gastroenterology.

More Less

Oct 24, 2016

Biohit Oyj’s Chinese joint venture to start production - Gastric cancer risk screening study progressing in China

Biohit Oyj stock exchange release October 24, 2016 at 09:30 am local time (EEST)

Biohit Oyj’s Chinese joint venture Biohit HealthCare (Hefei) Co. Ltd production facility has passed official test requirements and has been granted a license enabling production and sales of products. Biohit HealthCare (Hefei) Co. Ltd will start manufacturing of the globally unique GastroPanel®-products developed by Biohit Oyj for the Chinese market, and the first shipments will go to fill orders relating to the ongoing gastric cancer risk screening study which has been expanded to cover over 150 hospitals and expected to be concluded by the end of 2016 on part of the patient screening. The study will continue with statistical data analysis and reporting from various municipalities and hospitals that have taken part in the study. The reporting and analysis phase is expected to be completed during 2017. The results of the analysis will determine if a population based screening program is feasible. In the meantime sales of GastroPanel®-tests has continued in the 14 provinces where price approval has been granted. Biohit Oyj will supply the necessary raw materials and reagents used in production.

More Less

Sep 21, 2016

The first meta-analysis of the scientific studies conducted with GastroPanel® has been completed – the test is accurate for diagnosing atrophic gastritis

21.09.2016 09:30 Biohit Oyj Press Release September 21, 2016 at 09:30 am local time (EEST)
 
The first meta-analysis of the scientific studies conducted with GastroPanel® test has been completed. GastroPanel® is a unique test for diagnosing helicobacter gastritis (infection) and atrophic gastritis developed from it.  Atrophic gastritis, which is usually asymptomatic, can be detected only with GastroPanel® or gastroscopy and biopsy examination. Particularly for this reason, a stomach cancer developed as a result is diagnosed at late stages, when the prognosis is usually very poor.
 
The meta-analysis included systematically all the studies analysing the sensitivity and specificity of GastroPanel® test in diagnosing atrophic gastritis. Although there is variation between individual studies, results of the meta-analysis confirm that GastroPanel® is a sensitive and specific test for detecting atrophic gastritis in both corpus and antrum of the stomach. The scientific report of the meta-analysis has been accepted for publication in Anticancer Research journal (1).

More Less

Sep 2, 2016

Glomedics to distribute Biohit Lactose Intolerance Quick Test in South Korea

Biohit Oyj and Glomedics have signed an agreement for the distribution of the Biohit Lactose Intolerance Quick Test in South Korea.

Lactose Intolerance Quick Test (LIQT) developed by Biohit allows the diagnosis of lactose intolerance from biopsy specimen. Lactose intolerance refers to the inability to digest lactose, the sugar present in milk. A normal small intestine produces lactase enzyme that catalyses hydrolysis of lactose into glucose and galactose for normal digestion. In people with lactase deficiency, undigested lactose causes gastrointestinal problems, e.g. abdominal bloating and cramps, flatulence, diarrhoea, nausea, or vomiting.  

In endoscopy-referred patients, a biopsy from the upper part of the small intestine can be taken simultaneously for lactose intolerance testing. Biohit LIQT detects in 20 minutes, whether or not the lactase enzyme is present in the biopsy specimen. Biohit LIQT has been shown to have a superior sensitivity compared to competing methods, such as the hydrogen breath test (HBT)*.

CEO C.G. Chung., Glomedics: ‘It is our honour to be partner with Biohit Oyj and to distribute Lactose Intolerance Quick Test that is more unique, convenient and accurate than other diagnostic tests.  I am confident of the Lactose Intolerance Quick Test and sure that it will be the gold standard and routine test for patients with suspected lactose intolerance in Korea. We have started the registration in Korea required to obtain the marketing authorisation for the test.’    

CEO Semi Korpela, Biohit Oyj: ‘In Korea there is a promising market for the Lactose Intolerance Quick Test. It is estimated that 90% of Asians suffer from lactose intolerance, which, however,frequently remains undiagnosed and untreated for years.'

*Ojetti V, La Mura R et al., Dig Dis Sci 2008; 53(6): 1589-92

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

 

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com  www.biohithealthcare.com/additional-information
 

Glomedics in brief

Glomedics is a diagnostic company headquartered in Goyang, Korea. Glomedics has a long-term and experienced sales network in gastrointestinal diagnostics market. The company has distributed functional disease diagnostics products for 20 years in Korea. Glomedics has sound and long-term relationships with most of the Korean University Hospitals.

More Less

Aug 22, 2016

Beijing HuayiHuilang Medical Instrument Co., Ltd. to distribute GA-mapTM Dysbiosis Test in China

Biohit Oyj and Beijing HuayiHuilang Medical Instrument Co., Ltd. have signed an agreement for the distribution of the GA-mapTM Dysbiosis Test in China.

GA-mapTM Dysbiosis Test allows measuring of gut microbiota imbalance, dysbiosis. The test is particularly suitable for patients suffering from inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). The test reports the intestinal bacterial profile and balance of the microbiota, which helps guiding the treatment or changing the dietary habits in cases of imbalance.  GA-mapTM Dysbiosis Test is CE-marked. Biohit Oyj has an exclusive right to distribute the test in Finland and China.

General Director Yisheng Fang, Beijing HuayiHuilang Medical Instrument Co., Ltd.: ‘Dysbiosis causes not only gut diseases, but is associated with other health problems as well. However, there has not been any reliable diagnostic test like Biohit Dysbiosis test in China as yet. China has a large and potential market for Dysbiosis Test. We have started the registration process in China that is a prerequisite for the marketing authorisation of the test.’

CEO Semi Korpela, Biohit Oyj: ‘Numerous studies have suggested the role of gut microbiota in gastrointestinal diseases, but the links between dysbiosis and IBS or IBD have been discovered only recently.  Following the new agreement, Beijing HuayiHuilang Medical Instrument Co., Ltd receives the rights to distribute GA-mapTM Dysbiosis Test in China, which is an important market area for Biohit.’

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com  www.biohithealthcare.com/additional-information
 

Beijing HuayiHuilang Medical Instrument Co., Ltd. in brief

Beijing HuayiHuilang Medical Instrument Co., Ltd. (Huayi) is a professional medical device and IVD distribution company headquartered in Beijing, China. Huayi has a highly experienced sales team and well-established sales network in all regions of China. The company has cooperation with well-known clinical experts and doctors and a strong ability to promote sales. The customers of Huayi can be found all over China.

More Less

Aug 3, 2016

Simultaneous testing of GastroPanel® biomarkers is possible – preliminary study results have been completed

In accordance with the licensing agreement signed in 2013 between Biohit Oyj and clinical diagnostic company Randox Laboratories Ltd., an initial study investigating the simultaneous determination of Biohit GastroPanel® biomarkers using Randox Biochip Array Technology (BAT) has now been completed. According to preliminary study results, BAT simultaneously detects three key GastroPanel® biomarkers from a single patient sample. This multi-analytical approach would result in GastroPanel® becoming a more cost-effective, user-friendly test for diagnosis of dyspeptic symptoms and the screening of gastric cancer risk.

The Biohit GastroPanel® consists of four biomarkers: Pepsinogen I and II (PGI, PGII), Gastrin-17 (G-17) and Helicobacter pylori -antibodies. Biohit GastroPanel® is a unique Helicobacter pylori blood test providing valuable information on the health of the stomach. In addition toHelicobacter pylori infection (gastritis), this test detects atrophic gastritis with related risks, e.g. gastric and oesophageal cancer, malabsorption of vitamin B12 and a decreased acid output. Randox BAT allows the simultaneous determination of three of the GastroPanel® analytes (PGI, PGII and G-17), from a single patient sample. This is a more efficient test method compared to single analyte detection used in the previous test version. In the near future, the three analyte GastroPanel® biochip array in combination with a separate GastoPanel® biochip array for detection of Helicobacter pylori antibodies will be released and results reported through GastroSoft.

Chief Scientific Officer John Lamont, Randox Laboratories Ltd.: ‘This study indicates that Biochip Array Technology provides a robust platform for the simultaneous measurement of the unique GastroPanel® biomarkers Pepsinogen I, Pepsinogen II and Gastrin 17 from a single patient sample. Biochip Array Technology uses low sample volume and will offer a cost effective and efficient method for patient testing.’

CEO Semi Korpela, Biohit Oyj: ‘These preliminary results are promising. Simultaneous determination of GastroPanel® facilitates the reliable screening and diagnosis of Helicobacter pylori and its potential sequels, like gastric cancer and vitamin B12 deficiency, thus making GastroPanel® cost-efficient test for the use in the primary healthcare and screening.’

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

www.biohithealthcare.com/additional-information

www.gastropanel.com/decision-makers/screening-model
 

Biohit Oyj in brief

Biohit is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

Randox Laboratories Ltd. in brief

Randox is an international company with over 30 years’ experience in research, development, manufacture and marketing of high quality diagnostic reagents and equipment for laboratory medicine. The range of products includes, the innovative Biochip Array Technology, clinical chemistry analysers, reagents, external quality assurance schemes, quality control materials and an extensive life sciences portfolio. Randox is dedicated to improving health worldwide and the headquarters is located in the UK. www.randox.com

More Less

Aug 1, 2016

GastroPanel® detects risk factors of gastric cancer – a population-based screening study in Russia has been completed

A population-based screening study for gastric cancer risk has been completed in Russia. The study results confirm the previous study results showing that GastroPanel® detects patients at increased risk for developing gastric cancer. GastroPanel® test was used for screening of randomly selected asymptomatic people in a country with high incidence of gastric cancer. The results have been published in the August issue of an international cancer journal Anticancer Research.

The study was conducted in 2013-2015 in St. Petersburg. A cohort of 918 asymptomatic subjects (aging 50 years), were randomly selected among attenders of two hospitals for GastroPanel® testing.  GastroPanel® is an ELISA-based blood test measuring the blood plasma levels of four biomarkers. GastroPanel® is used in diagnosis of Helicobacter pyloriinfection (HP), atrophic gastritis (AG) and the gastric cancer risk resulting from them.

GastroPanel® test is a specific screening test for the risk factors of gastric cancer

In the study, HP infection without AG was detected in 76.7% of the study subjects, while AGwas diagnosed in 10.8%. All GastroPanel® results indicating AG and a randomly selected 5% of the GastroPanel test-negative subjects were examined by gastroscopy and biopsies. GastroPanel®-test proved to be both sensitive and specific (>95%) in detection of the two gastric cancer risk conditions (HP and AG).

Chief Medical Director, Kari Syrjänen, Biohit Oyj: ‘Globally, gastric cancer is the fifth most common malignancy. For cancer prevention, a systematic screening of the risk factors, HP and AG, would be important. The present study shows that GastroPanel® is an accurate test for detection of the individuals at risk for gastric cancer.’

CEO, Semi Korpela, Biohit Oyj: ‘With the GastroPanel® test, gastric cancer risk conditions can be found years before the development of cancer, which offers an opportunity for effective primary prevention. It is well known also in Finland, that still many gastric cancer cases lead to examination and treatment only, when the patient already has alarming symptoms and a poor prognosis. An organised population-based screening of the gastric cancer risk groups should be seriously considered also in Finland, as it saves significantly healthcare costs. The unique andhighly informative Finnish GastroPanel® innovation would offer an opportunity for this.’

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
www.biohithealthcare.com/additional-information
www.gastropanel.com/decision-makers/screening-model

 
Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

More Less

Jul 11, 2016

Beijing HuayiHuilang Medical Instrument Co., Ltd. to distribute Biohit Celiac Disease Quick Test in China

Biohit Oyj and Beijing HuayiHuilang Medical Instrument Co., Ltd. have signed an agreement for the distribution of the Biohit Celiac Disease Quick Test in China.

Biohit Celiac Disease Quick Test allows the diagnosis of celiac disease from a fingertip blood sample within ten minutes. Celiac disease is a relatively common underdiagnosed autoimmune disease causing different types of stomach problems. In celiac patients the rye, wheat and barley protein (gluten) causes inflammation of the small intestine mucosa and damages the microvilli. This in turn interferes with the absorption of nutrients.

Celiac Quick Test measures all three celiac disease antibodies produced in the body. These are transglutaminase antibodies IgA/IgG/IgM. Negative results exclude celiac disease.

General Director Yisheng Fang, Beijing HuayiHuilang Medical Instrument Co., Ltd.:  'In China, celiac disease has so far received insufficient attention. Biohit’s sensitive and specific Celiac Disease Quick Test helps detect celiac disease patients among those with dyspeptic symptoms. The right diagnosis and a strict diet will bring significantly better life quality to these patients.”

CEO Semi Korpela, Biohit Oyj: ‘We are expanding our business operations in the large Chinese market by starting a cooperation with Beijing HuayiHuilang Medical Instrument Co., Ltd. In China there is an increasing need and expanding market for Celiac Disease Quick Test. We have started the registration in China required to obtain the marketing authorisation for the test.'

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

 
Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com  www.biohithealthcare.com/additional-information
 

Beijing HuayiHuilang Medical Instrument Co., Ltd. in brief

Beijing HuayiHuilang Medical Instrument Co., Ltd. (Huayi) is a professional medical device and IVD distribution company headquartered in Beijing, China. Huayi has a highly experienced sales team and well-established sales network in all regions of China. The company has cooperation with well-known clinical experts and doctors and a strong ability to promote sales. The customers of Huayi can be found all over China.

More Less

May 23, 2016

More scientific evidence on GastroPanel® test – the test predicts gastric cancer risk even at 15-year follow-up

Low Pepsinogen I level diagnosed with GastroPanel® test predicts the risk for stomach cancer even years in advance. The result is evident in two separate recent studies among Asian and Caucasian population, where the subjects were followed-up for several years after GastroPanel® testing. Low Pepsinogen I level in the blood sample accompanied by high Gastrin-17 level, is a sign of atrophic gastritis of the corpus. The latter is known to be a risk factor for gastric cancer. The long-term predictive value of GastroPanel® test as a predictor of this risk has not been previously confirmed in a Caucasian population.  

Biohit GastroPanel®-test consists of four biomarkers: Pepsinogen I and II (PGI, PGII), Gastrin-17 (G-17) and Helicobacter pylori -antibodies. The test is intended for diagnosis of Helicobacter pylori infection in dyspeptic patients and in health controls as well as for early detection and screening of atrophic gastritis and all associated risks caused by this infection or autoimmune disease. The test also reveals high acid output and its potential sequels. Asymptomatic atrophic gastritis, high acid output or symptomatic Helicobacter pylori infection are indications of gastroscopic examination (see Additional Information).

The two studies were conducted among Caucasian and Asian population

The first study was conducted among Caucasian population in Novosibirsk region in Western Siberia. A cohort of 9360 people was included in the study, derived from the local population, and the group was followed-up for 7-10 years to estimate the risk of gastric cancer. To calculate the predictive value of GastroPanel® test, 2 age- and sex-matched controls were selected for each gastric cancer patient.  Blood samples taken from all subjects at the beginning of the follow-up were analysed with GastroPanel® test.

The study conducted in Taiwan had a very similar study design. The cohort size was 3514 and the follow-up time was up to 15 years (1995–2010). During the follow-up, 14 persons died of gastric cancer. In a multivariate model adjusted for several variables, low PGI was the best predictor of gastric cancer. Risk ratio (RR=3.24) was almost identical with the risk ratio (RR=2.9) obtained for PGI/PGII ratio in the Novosibirsk study.

Chief Medical Director Kari Syrjänen, Biohit Oyj: ‘These two important studies based on a long-term follow-up show consistently that the markers of GastroPanel® test indicating atrophic gastritis are highly reliable  predictors of gastric cancer risk even at a 15-year time span. Similarly, the long-term negative predictive value of normal GastroPanel® test result is over 95 %, which helps identifying the high-risk persons also in a population-based screening.’

CEO Semi Korpela, Biohit Oyj: ’The two studies provide more convincing evidence that the cost-effective GastroPanel® innovation, providing a lot of information, is, among other things, an excellent test for screening of gastric cancer risk (see Additional Information).’

Articles:

Stomach-specific Biomarkers (GastroPanel) Can Predict the Development of Gastric Cancer in a Caucasian Population: A Longitudinal Nested Case-Control Study in Siberia (Kurilovich et al)Anticancer Research 36: 247-254 (2016).

The Association Between Serum Pepsinogen Testing and Death From Gastric Cancer: A sixteen-Year Population-Based Cohort Study (Lee et al.) Poster presentation at Digestive Disease Week, San Diego, California, May 22, 2016.

Additional information on GastroPanel® test can be found in the attachment.

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

More Less

May 18, 2016

Pooyandegan Pezeshki Pardis to distribute Biohit GastroPanel®-test in Iran

Biohit Oyj and Pooyandegan Pezeshki Pardis (3P) have signed an agreement for the distribution of the Biohit Unified GastroPanel® test in Iran.

GastroPanel® innovation is a stomach health test. The test is performed from a blood sample and designed for diagnosis of Helicobacter pylori infection and atrophic gastritis, irrespective whether caused by H. pylori infection or autoimmune disease. The test also enables to assess whether the patient is at risk for gastric or esophageal cancer, peptic ulcer disease or malabsorption of vitamin B12, calcium or iron.  Among dyspeptic patients, GastroPanel® helps identifying the patients who need further examinations. GastroPanel® consists of four biomarkers: Pepsinogen I and II, Gastrin-17 and H. pylori -antibodies. In the unified GastroPanel® test, the reaction conditions and solutions are uniform, which makes the test fast and easy to perform in the laboratory.  

CEO Ali Amari Allahyari, Pooyandegan Pezeshki Pardis: ‘We have signed a distributor agreement with the Finnish Healthcare company Biohit Oyj, to market, distribute and sell GastroPanel® test in Iran, where gastric cancer is a particularly common disease.'

CEO Semi Korpela, Biohit Oyj: ‘Iran is a high-incidence country for gastric cancer. We are starting now a co-operation with Iranian company Pooyandegan Pezeshki Pardis sharing our mission to improve clinical practices through innovations. The process for registration of the unified GastroPanel®-test in Iran has been initiated.’

Additional information on GastroPanel® test can be found in the attachment.

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

Pooyandegan Pezeshki Pardis in brief

Pooyandegan Pezeshki Pardis (3P) is an Iranian company, designing, developing, manufacturing and selling medical devices. In 3P we believe in innovation and creativity along with the highest quality and focus to offer the best products and services to our customers. The company’s headquarters is located in Tehran. www.3pardis.com

More Less

May 17, 2016

Atrophic gastritis and vitamin B12 deficiency remain often undetected in elderly people – early diagnosis is important to prevent complications

Early diagnosis of atrophic gastritis and vitamin B12 deficiency in elderly people is important in order to prevent, for instance, irreversible neurological complications. Atrophic gastritis is caused by Helicobacter pylori infection or autoimmune disease. Atrophic gastritis, related i.a. to risk for gastric cancer, can be one important reason leading to vitamin B12 deficiency. A majority of B12 vitamin deficient cases in Estonia but less than 25% in Finland remains undiagnosed. This is evident in a study comparing prevalence of atrophic gastritis and vitamin B12 deficiency in elderly people in Finland and Estonia

A majority of B12 vitamin deficient cases in Estonia but less than one fourth in Finland remains undetected

In the study, 209 men and women beyond 80 years of age in two assisted-housing facilities in Tampere and Tartu were examined with Biohit active vitamin B12 test and GastroPanel® stomach health test detecting atrophic gastritis in addition to Helicobacter pylori infection (see Additional Information). These laboratory results were linked with the medical history of the study subjects. The study was carried out by Biohit in collaboration with local doctors.

In the study, atrophic gastritis was found in 12% of study subjects in Finland and in 15.6% of those in Estonia.  Of the cases with vitamin B12 deficiency found in the study, a vast majority (92%) in Estonia but less than one fourth (23.5%) in Finland had remained previously undetected.

Early detection of the risk for vitamin B12 deficiency is necessary

Vitamin B12 deficiency results rarely from diet. Usually, it is caused by often asymptomatic atrophic gastritis, resulting in acid-free stomach, which in turn leads to malabsorption of this vitamin. Vitamin B12 deficiency caused by atrophic gastritis is a slow process, which can lead to peripheral neuropathy, depression and dementia. These complications begin to develop even before the deficiency can be detected with the vitamin B12 test.

Chief Medical Director Kari Syrjänen, Biohit Oyj: ‘In order to prevent the complications caused by vitamin B12 deficiency, the risk for deficiency has to be detected early enough. GastroPanel® test is ideal for screening of the risk groups for vitamin B12 deficiency. The test is producing a lot of other information as well. Additionally, it is recommended to measure vitamin B12 levels in people over 60 years of age.’

CEO Semi Korpela, Biohit Oyj: 'There is an increasing need for GastroPanel® test and vitamin B12 measurement, particularly among the elderly people.'

Manuscript: Atrophic gastritis (AG) and its clinical sequels among elderly people in Finland and Estonia. A comparative study using GastroPanel and B12-vitamin testing of the residents in assisted-housing facilities (Riitta Aine, Elli Kahar, Katriina Aitokari, Johanna Salminen, Carita Eklund, Lea Paloheimo, Ants Peetsalu, and Kari Syrjänen) has been submitted for evaluation in an international geriatric journal.

 Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

More Less

Apr 14, 2016

Biohit Oyj starts inviting participants in the confirmatory smoking intervention trial

Biohit Oyj starts inviting the smoking volunteers in the confirmatory smoking intervention trial. The clinical confirmatory trial has obtained ethical approval from the regional ethical committee requested from all clinical studies before they can be started.

The test compound is Acetium lozenge binding acetaldehyde in the saliva into a harmless compound. The aim of the confirmatory study is to affirm the promising results obtained in the previous smoking intervention trial with Acetium lozenge. If successful, the trial gives adequate power to confirm, that the Acetium lozenge represents a breakthrough in the development of smoking intervention methods.

Enrollment for the study has begun

Persons who may be suitable for the study 

are males or females aged 18-65 years 
smoke regularly (only cigarettes) 
want to quit smoking  
have no serious smoking related illnesses (such as chronic obstructive pulmonary disease, lung cancer)  
are not pregnant or breastfeeding  
are not part of another clinical trial  
don’t use any prescription medication for smoking cessation 
have not been part of the first smoking intervention trial by Biohit

Enrollment (only in Finland) is available online at Kuulas Helsinki: http://www.kuulas.fi, by phone 040 6792451 or by email contact@kuulas.fi.

A cohort of 1,800 active smokers motivated to quit will be invited in the study. The study will be conducted as a randomized, placebo-controlled, double-blind clinical trial, where half of the subjects will receive the active compound and the other half will receive a placebo. The study is conducted in cooperation with research agency Kuulas Helsinki and the study covers whole Finland.

CEO Semi Korpela, Biohit Oyj: ‘Enrollment of smoking volunteers in the trial will start immediately.’

The person-in-charge of the study is the Chief Medical Director of Biohit Oyj, MD, PhD, Professor Kari Syrjänen. The principal investigator at Kuulas Helsinki is Adjunct Professor, D.Soc.Sc., Anna Bäckström.

Additional information: 
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

More Less

Apr 13, 2016

The scientific report on Biohit’s first smoking intervention trial has been accepted for publication

The scientific report on the first smoking intervention study by Biohit has been accepted for publication in a widespread international journal Anticancer Research. The trial using Acetium lozenge was completed in November 2015. According to the trial, the Acetium lozenge is a promising novel method to assist in smoking cessation.

Chief Medical Director, Professor Kari Syrjänen, Biohit Oyj: ‘Acetium lozenge is a safe promising product for smoking cessation because it is all natural and it does not contain any nicotine. The product has no restrictions for use or a maximum allowable dosage. A smoker can use it simultaneously with cigarettes until making the decision to quit smoking.’

CEO, Semi Korpela, Biohit Oyj: ‘Unlike many commonly used current intervention methods, of which medical treatment can cause severe side effects and nicotine products maintain nicotine addiction, the Acetium lozenge is a product, which has no known side effects. Despite the fact that the product efficiently binds carcinogenic acetaldehyde dissolved into saliva from cigarette smoke, transforming it into a harmless compound, and in addition, promotes oral health, unlike the currently available medications and nicotine products, Biohit Oyj recommends quitting smoking because of the smoking health hazards. As soon as the ethical approval has been obtained Biohit starts a larger trial which aims to confirm the previous promising results of the efficacy of Acetium lozenge as a method to assist in smoking cessation.’

Additional information:

Chief Medical Director of Biohit Oyj, Professor, MD, PhD Kari Syrjänen
kari.syrjanen@biohit.fi

CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

More Less

Apr 8, 2016

Helicobacter pylori infection increases the risk for gastric cancer – Long-term follow-up of the screened population has been completed

Additional confirmatory scientific evidence is obtained regarding the association betweenHelicobacter pylori and gastric cancer. A long-term follow up of the population screened in 1994-1996 has been completed, and the results have been accepted for publication in Scandinavian Journal of Gastroenterology. The journal is an esteemed and widespread scientific publication in the field.

The study confirms previously reported results. Even Helicobacter pylori infection alone increases significantly the risk for gastric cancer. The risk increases substantially further, when untreated infection has progressed to atrophic gastritis.

First population-based screening with the GastroPanel biomarkers

In 1994-1996, a population-based screening study was conducted in collaboration with researchers from the Finnish Cancer Registry. In this study, over 12 000 men aged 50–65 years from two cities of southern Finland were examined with two GastroPanel biomarkers,Helicobacter pylori -antibody test and pepsinogen I assay. The screened population was followed-up passively until 2011, when the results were linked to the Finnish Cancer Registry database, and the incidence of gastric cancer was assessed in the screened and control population.

Helicobacter pylori infection alone increases the risk of developing cancer six-fold

 Based on the test results, the subjects could be divided into three groups. The risk of cancer was assessed during 15-year follow-up period in these groups: 1) normal stomach 2)Helicobacter pylori infection without atrophic gastritis, and 3) atrophic gastritis.

Altogether, 65 new gastric cancers developed during the 15-year follow-up period in the whole screened population as follows:

7 cancers developed in persons with healthy stomach (incidence 8.7/100.000) 
50 cancers developed in persons with Helicobacter pylori infection but no atrophic gastritis (incidence 54/100.000), and 
8 new cancers developed in persons with atrophic gastritis (incidence 92.4/100.000)

Based on these figures, the authors calculated that the risk ratio (RR) for developing gastric cancer compared to healthy subjects was 5.8-fold in persons with untreated Helicobacter pyloriinfection and up to 9.1.-fold in those with atrophic gastritis.

Chief Medical Director, Kari Syrjänen, Biohit Oyj: ‘This is the first screening study of its kind based on purely population-derived sample using Biohit GastroPanel biomarkers. The study as a whole is well designed, in co-operation with the Finnish Cancer Registry, and it is unique of its kind. The results are very convincing and they provide further evidence to confirm thatHelicobacter pylori infection and the associated atrophic gastritis are two most important risk factors for gastric cancer.'

CEO, Semi Korpela, Biohit Oyj: ‘The study supports the view that it is possible to predict gastric cancer development with GastroPanel even years before the diagnosis of the disease. GastroPanel can also be used for primary diagnosis of dyspeptic patients. New gastric cancer cases are being detected in 600-700 Finns every year. The confirmed cancer risk is high enough to warrant serious considerations to introduce GastroPanel test for population-based screening in Finland.'

The report Risk of gastric cancer in Helicobacter pylori infection in a 15-year follow-up (Ilkka Vohlonen, Eero Pukkala, Nea Malila, Matti Härkönen, Matti Hakama, Veli Koistinen, Pentti Sipponen 2016) will be published in Scandinavian Journal of Gastroenterology.

More information on GastroPanel test can be found in the attachment.

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

More Less

Mar 17, 2016

Biohit and Tianjin Jingsheng Biological Technology Development Co. Ltd. to start co-operation

Biohit Oyj and Tianjin Jingsheng Biological Technology Development Co. Ltd have signed a distributor agreement for the distribution of the Biohit Calprotectin ELISA test in China.

Biohit Calprotectin test is a useful quick test for measuring calprotectin in a stool sample. The test is used to differentiate inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) as well as in monitoring of the treatment in IBD patients. Inflammatory bowel diseases are Crohn's disease and ulcerative colitis, diagnosed increasingly. Particularly ulcerative colitis is linked with an increased risk of colon cancer.

The test measures calprotectin released from the inflamed intestinal mucosa into faeces. Calprotectin is derived from the inflammatory cells, and its concentration in the faeces reflects the activity of the inflammation and the efficacy of the treatment in IBD patients. In patients with IBS, this test is usually negative.

General Director Zeng Zhao Hong, Tianjin Jingsheng Biological Technology Development Co. Ltd.:  'In China there seems to be differences in prevalence of IBD between rural and urban population. The disease is increasing particularly among young people. Fecal calprotectin is an emerging biomarker of gut inflammation. Biohit Calprotectin test differentiates reliably IBD and IBS and reduces significantly the need of colonoscopies.'

CEO Semi Korpela, Biohit Oyj: ‘We are starting a co-operation with Tianjin Jingsheng Biological Technology Development Co. Ltd in the large Chinese market. We have started the registration in China required to obtain the marketing authorisation for the product.'
 

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
 

Tianjin Jingsheng Biological Technology Development Co. Ltd in brief

Tianjin Jingsheng Biological Technology Development Co. Ltd. (TJJS) is a globally operating immunoassay and molecular biology company. TJJS is located in China. For over 20 years, TJJS has continuously marketed immunoassay kits, biochemical reagents, PCR products, cytopathological test reagents and instruments. TJJS offers professional and timely after-sales service. The customers of TJJS can be found all over Asia. www.jsbiotech.com

More Less

Mar 2, 2016

Biohit and OnSite Diagnostic Labs India Pvt Ltd. to start co-operation

Biohit Oyj and Onsite Diagnostic Labs India Pvt Ltd have signed a distributor agreement for the unique Biohit diagnostic portfolio in India. OnSite Diagnostic Labs India Pvt Ltd will solely focus on the marketing of Biohit's tests in India. Diagnostic tests covered by the distribution agreement include e.g.:

GastroPanel is the test for stomach health. This test is performed from a blood sample and designed for accurate diagnosis of H. pylori infection and atrophic gastritis, irrespective whether caused by H. pylori infection or autoimmune disease. This test enables to assess whether the patient is at risk for gastric or esophageal cancer, peptic ulcer disease or malabsorption of vitamin B12, calcium or iron.  GastroPanel also helps identifying the patients who need further examinations. (Attachment: Additional information).

Active vitamin B12 test measures the blood levels of circulating active B12 vitamin (holotranscobalamin). Vitamin B12 deficiency can occur in seemingly healthy people, and the risk increases with age and after long-term use of proton pump inhibitors (PPIs).  

Celiac Quick test measures elevated tTG IgA/G/M antibodies in serum, diagnostic to celiac disease (CD).  The test contributes to substantial savings in healthcare costs, by reducing the number of unnecessary endoscopies.

Calprotectin test is used to differentiation of inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) as well as in monitoring of the treatment in IBD patients.

ColonView-FIT is a quick test for detection of fecal occult blood (FOB), used in screening of colorectal cancer. This highly sensitive test detects FOB derived from both the upper and lower gastrointestinal tract, thus facilitating the diagnosis of even small benign lesions (polyps) and cancer precursor lesions (adenomas).

CEO Jagdeep Singh, OnSite Diagnostic Labs India Pvt Ltd: ‘Our mission of preventing people becoming patients by focusing on key disease areas contributing to death rates in India and bringing advanced technologies for early diagnosis, is becoming realized by the partnership with Biohit in the gastroenterology field. Utilizing the innovative tests from the Biohit portfolio, based on advanced technology, we are making early stomach health screening more accessible and affordable for Indians everywhere.’

CEO Semi Korpela, Biohit Oyj: ‘We are very excited about the co-operation with OnSite Diagnostic Labs India Pvt Ltd, sharing our vision of the importance of early diagnosis of GI tract related diseases, and the registration in order to obtain the marketing authorization for the products has started.’
 

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861

investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
 
OnSite Diagnostic Labs India Pvt Ltd in brief

OnSite Diagnostic Labs India Pvt Ltd will market Biohit tests through its CheckMyHealth initiative. CheckMyHealth is devoted to screening, detecting and preventing the top killer diseases that affect Indians today. Together with Biohit CheckMyHealth is launching a unique portfolio of tests to help and treat potential problems before they become severe. http://checkmyhealth.com/

More Less

Feb 15, 2016

Biohit Oyj starts a confirmatory smoking intervention trial

Biohit Oyj starts a confirmatory clinical trial for smoking intervention in cooperation with research agency Kuulas Helsinki.  The aim of the study is to confirm the promising results obtained in the previous clinical trial aimed at smoking cessation. If successful, the trial gives adequate power to confirm, that the Acetium lozenge is a breakthrough in the development of smoking intervention methods.

Biohit Oyj implemented a clinical smoking intervention trial in 2013–2015. The study was based on a hypothesis that acetaldehyde, in addition to nicotine, is a significant factor causing and maintaining smoking dependence (1). Acetaldehyde dissolved into saliva from cigarette smoke, might act with certain natural amino acids to form condensation compounds called Harmans. These inhibit monoamine oxidase (MAO) – an enzyme in the central nervous system, which plays a key role in mediating the rewarding effects of smoking in the brain. It has been suggested that cigarette smoke-derived acetaldehyde has reinforcing effects on nicotine addiction and thereby help maintaining the behavioral sensitization to tobacco. Blood Harman levels among smokers are 2-10 times higher than in non-smokers (1). It was reasoned that this reaction could be interfered by effective binding of carcinogenic acetaldehyde in the saliva (2) into a harmless compound using the Acetium-lozenge containing slowly releasing L-cysteine.

Compared to the placebo, the likelihood of smoking cessation among users of the test substance during the trial was up to 1.65-fold (i.e., 65 % higher probability). This figure favorably competes with those reported in large international studies for nicotine replacement therapy (NRT) (3). The results were promising enough to warrant a new, larger confirmatory study.

A cohort of 1,800 voluntary smokers will be invited to the new study, to be randomly allocated into two groups of equal size. The study design is otherwise similar to the previous intervention trial.

CEO Semi Korpela, Biohit Oyj: “The new study is implemented with the same study design and population sampling than the previous trial.  We expect the new study to confirm the promising previous results. Unlike many commonly used current intervention methods, of which some medical treatment can cause severe side effects and nicotine products maintain the nicotine addiction, the Acetium lozenge is a product, which has no known side effects. For this reason, there are no restrictions for use or a maximum allowable dosage, and a smoker can use it simultaneously with cigarettes until making the decision to quit smoking. Regardless of the used intervention method, the decision to quit smoking, however, has to be made in person. Despite the fact that the Acetium lozenge efficiently binds carcinogenic acetaldehyde dissolved into saliva from cigarette smoke, transforming it into a harmless compound, and in addition, promotes oral health, unlike the currently available medications and nicotine products, Biohit Oyj recommends quitting smoking because of the smoking health hazards.’

 

Biohit Oyj Stock Exchange Release 4.11.2015 Acetium lozenge – a promising novel method to assist smoking cessation

Biohit Press Release 29.11.2013 Biohit Oyj to start a clinical intervention trial with Acetium® lozenge aimed at smoking cessation

References:

1.    Talhout R, Opperhuizen A, van Amsterdam JG. Role of acetaldehyde in tobacco smoke addiction. Eur Neuropsychopharmacol 2007;17:627-636.

2.    Salaspuro VJ, Hietala JM, Marvola ML, Salaspuro MP. Eliminating carcinogenic acetaldehyde by cysteine from saliva during smoking. Cancer Epidemiol Biomarkers Prev 2006;15:146-149.

3.    Lemmens V, Oenema A, Klepp KI, Brug J. Effectiveness of smoking cessation interventions among adults: a systematic review of reviews. Eur J Cancer Prev 2008;17:535–544.

Additional information:

Chief Medical Director of Biohit Oyj, Professor Kari Syrjänen
kari.syrjanen@biohit.fi

CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

Kuulas Helsinki in brief

Kuulas Helsinki is specialized in producing psychological insight into measurable and profitable business growth. We are a strategic partner for consumer understanding and we a have ten-year history in the industry. We work effortlessly in areas that require multivariate analysis as well as in-depth qualitative analysis methods. Kuulas Helsinki is a member of FAMRA. We follow the ESOMAR rules of good scientific practice. http://www.kuulas.fi/

More Less

Jan 5, 2016

Biohit Oyj buys a share of Norwegian Genetic Analysis AS company with a directed share issue

Biohit Oyj and Genetic Analysis AS have signed a share exchange agreement through which Biohit Oyj acquires ownership of 18 % of shares in the company. In addition to this the companies have signed a distribution agreement giving Biohit Oyj a right to sell Genetic Analysis AS’s Dysbiosis Test globally under the Biohit brand and exclusively in Finland and in China. In the future, Genetic Analysis will also operate as a distributor to Biohit Oyj’s products and services in Norway.

Genetic Analysis AS is a Norwegian molecular diagnostic company with core competence in mapping of colon microbiota i.e. microbial flora. The company has invested significantly in product development and is expected to begin the FDA application process for its product in 2016 in the United States. Following the share exchange and the distribution agreement, Biohit gains a new diagnostic test in its portfolio based on patented gene technology. With the Dysbiosis test, an imbalance in the gut microbiota can be identified, which in turn can be involved in major diseases (IBD i.e. inflammatory bowel disease and Crohn’s disease). Identifying the microbiota imbalance and mapping the bacteria is, in many diseases, key in providing successful treatment to the patient. The Dysbiosis test is CE marked, launched and it has a marketing authorization in Europe.

In consideration for ownership of 18 % of Genetic Analysis AS, Biohit Oyj will issue 350,000 pcs of new Biohit Oyj’s series B shares. These shares include a transfer restriction ending on 30th of June 2017. However, upon fulfillment of certain contractual conditions Genetic Analysis AS is permitted to transfer 150.000 pcs of the series B shares within one year of the fulfillment of the condition. The shares produce the right to dividends as well as other shareholder rights in Biohit Oyj and accordingly in Genetic Analysis AS as of the date of the registration with the Trade Register. Biohit Oyj’s Board of Directors has received the required issue authorization from the General Meeting on April 14, 2014. Execution of the share exchange requires authorization by the Genetic Analysis AS General Meeting. The registration for Biohit Oyj series B shares is estimated to take place within two weeks after the decision of the Genetic Analysis’ General Meeting, but no later than the end of February 2016.

As a result of the share issue, the total number of Biohit Oyj shares increases to 14,698,533shares (14,348,533) and the number of B-shares to 11,723,033 shares (11,373,033). The company's share capital remains unchanged at 2,350,350.81 euros. The new shares correspond to a 2.4% share of Biohit’s total outstanding shares and a 0.49% share of voting rights after the registration.

CEO Semi Korpela, Biohit Oyj: "The gut microbiota plays a central role in human health. The Genetic Analysis Dysbiosis test complements well the Biohit product offering. Genetic Analysis AS will benefit from Biohit’s well-established partner and distribution network in key geographical areas such as China, while Biohit gains a promising cutting edge technology product in its growing portfolio.”

CEO Ronny Hermansen, Genetic Analysis AS: “Biohit has products promoting disease prevention and saving health care costs. Through the agreement with Biohit, we expand our product portfolio further, secure a faster commercialization in Eastern Europe and Asia, especially in China, and are well-positioned for fast growth in 2016. Through Genetic Analysis, Biohit will get a strong addition to its product portfolio, a dedicated distribution partner in Norway for its products, and access to key competence like the Genetic Analysis Scientific Advisory Board, consisting of key opinion leaders within the gastroenterological field in the Nordic countries as well as Central Europe."

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
 
Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

 Genetic Analysis AS in brief

Genetic Analysis has developed and launched the first bacterial gene-based clinical test for the mapping and diagnosis of diseases related to dysbiosis and imbalances in the digestive system. The company markets the GA-map™ technology to three market segments: commercial routine clinical testing, pharma companies and the research market. Genetic Analysis was established in 2008 and is based on research done by Professor Knut Rudi and Nofima Mat in Ås, Norway. www.genetic-analysis.com/

More Less

About us

Company details

Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit’s mission is “Innovating for Health”.

Biohit shoulders its social responsibility by creating innovative new technologies and services that help physicians and research institutions to promote diagnostics and research. They can also prevent diseases of the gastrointestinal tract, exposure to acetaldehyde, human suffering and financial loss, thereby generating wellbeing. Being a socially responsible company, we feel it is our duty to raise public awareness of acetaldehyde, a group 1 carcinogen, and to innovate and develop the marketing of our products and services, ensuring their maximum availability to the public. Biohit is headquartered in Helsinki and has subsidiaries in China and the UK. Biohit’s Series B share (BIOBV) is quoted on NASDA Q OMX Helsinki since 1999, Small cap/Healthcare.

 

Innovations

Gastrointestinal disorders are a growing worldwide phenomenon that also involves significant medical, ethical and financial issues. Gastrointestinal disorders are also the most common cause of complaints regarding treatment, or insufficient treatment. Such problems are essentially related to issues affecting the general healthcare sector and growing financial constraints caused by the ageing population. GastroPanel, Acetium and ColonView are safe, ethical and costefficient innovations for diagnosing and preventing gastrointestinal diseases and the associated risks.

 

www.biohithealthcare.com

More Less

Company data

Sales volume

1-9 Mio US $

Export content

> 75%

Number of employees

20-49

Foundation

1988

Area of business

Diagnostics